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Abstract  Breast  lumps  detected  during  pregnancy  are  generally  benign  and  reﬂect  ﬁbroade-
noma, lactating  adenoma,  cysts,  infarction  of  the  breast  or  galactocele.  Although  rare,  the
possibility of  breast  cancer  must  also  be  considered  to  avoid  any  delays  in  diagnosis.  After
patient questioning  and  clinical  examination,  the  ﬁrst  imaging  modality  to  use  is  ultrasound.
No further  assessment  is  called  for  if  lesions  are  categorized  as  BI-RADS  2  and  no  suspicious  clin-
ical signs  are  observed.  Depending  on  the  clinical  setting,  lesions  classiﬁed  BI-RADS  3  require
monitoring  and  mammographic  assessment  (which  can  be  helpful  in  diagnosing  cancer  and  incurs
no risk  to  the  embryo  or  fetus).  If  the  clinical  signs  are  unclear  and/or  the  lesion(s)  are  cat-
egorized  as  ≥  BI-RADS  4a,  then  mammography  and  often  biopsy  should  be  performed.  Strict
BI-RADS scoring  (American  College  of  Radiology)  should  be  applied,  bearing  in  mind  that  benign
lesions can  appear  suspicious  during  pregnancy,  and  some  cancers  can  exhibit  what  seem  to  be
reassuring  characteristics.© 2015  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
The breast during pregnancy
Physiological changes to the breast during pregnancy [1—3]
Estrogen  and  progesterone  production  by  the  corpus  luteum  during  the  ﬁrst  trimester  of
pregnancy  and  by  the  placenta  during  the  second  trimester,  lead  to  lobule  and  duct  prolifer-
ation  and  development,  involution  of  adipose  tissue  and  increased  breast  vascularization.
Mononuclear  inﬂammatory  cells  also  inﬁltrate  the  breast  tissue.  Estrogens  stimulate  the
developing  lactiferous  duct  system,  whereas  progesterone  stimulates  lobule  development.
The  proliferative  process  is  most  pronounced  during  the  ﬁrst  20  weeks  of  pregnancy.
∗ Corresponding author.
E-mail address: adriana.langer@curie.fr (A. Langer).
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Lobule  growth  continues  during  the  2nd  and  3rd
rimesters  via  cellular  proliferation  as  well  as  increased  cell
ize.  Myoepithelial  cells  become  ﬂattened  and  less  promi-
ent  whereas  epithelial  cells  are  enlarged.  During  the  2nd
rimester,  secretory  substances  accumulate  in  the  epithelial
ells  of  lobule  acini,  and  during  the  3rd  trimester  increased
evels  of  prolactin  promote  alveolar  cell  differentiation  and
nitiate  lactogenesis.
During  the  second  half  of  pregnancy,  the  proliferative
rocess  slows  and  changes  to  the  secretion  pathway  involved
n  milk  production  increase.  Lobule  size  increases  and  inter-
obular  adipose  tissue  disappears  until  lobules  are  separated
nly  by  thin  layers  of  connective  tissue.
The  changes  to  the  secretion  pathway  do  not  occur  evenly
ithin  the  breast  during  pregnancy.  Some  authors  consider
hat  localized  hyperplasic  lactating  adenoma,  that  can  cause
ne  or  more  palpable  lumps  visible  using  imaging  tech-
iques,  is  an  extreme  manifestation  of  the  heterogeneity
f  this  process  [1].
Some  of  the  histological  changes  that  occur  during  preg-
ancy  can  be  visualized  such  as  physiological  adenosis,
alciﬁcations  within  milk-secreting  acini  and  dilated  ducts.
reexisting  lesions  may  undergo  changes  due  to  variations  in
he  hormonal  environment;  thus  ﬁbroadenoma,  hamartoma
nd  ﬁbrocystic  breast  disease  may  show  secretory,  cystic
nd/or  necrotic  changes.
linical changes
linical  examination  reveals  a  darkening  of  the  nipple  and
reola,  a  more  prominent  nipple  and  dilated  superﬁcial  skin
eins  as  from  the  end  of  the  ﬁrst  trimester.  During  the
nal  stages  of  pregnancy,  breast  adipose  tissue  nearly  com-
letely  disappears  and  is  replaced  by  hard,  tight  lobes;  the
kin  becomes  thinner.  A  little  colostrum  may  be  released
y  breast  massage.  Clinical  examination  can  be  challenging
ue  to  the  increased  size  of  the  breasts,  their  sensitivity  and
specially  their  harder,  more  nodular  consistency.
A  previously  palpable  lump  can  be  concealed  during  preg-
ancy  by  hypertrophic  breast  tissue,  or  may  increase  in  size,
ence  the  importance  of  examining  the  patient’s  breasts  at
he  beginning  of  pregnancy  and  then  at  regular  intervals
uring  its  course.
hanges in imaging ﬁndings
uct  ectasia  is  frequently  observed  using  ultrasound.  The
reast  is  more  hypoechoic  due  to  lobular  hyperplasia  and
uct  dilation;  its  echogenicity  is  more  or  less  homogeneous.
Mammograms  of  pregnant  women  generally  show  a  higher
issue  density  because  of  the  young  age  of  the  women  but
lso  due  to  glandular  development  and  adipose  tissue  atro-
hy,  which  decreases  the  sensitivity  of  mammography.  Even
o,  mammography  remains  a  very  helpful  modality  for  diag-
osing  breast  cancer  and  should  therefore  be  performed  if
here  is  the  slightest  doubt.
Sometimes  benign,  round  and  regularly-shaped  secretory
icrocalciﬁcations  may  be  observed.
Pre-pregnancy  assessment  is  important  to  monitor
hanges  such  as  increased  size  or  heterogeneity  of  existing
esions  (particularly  ﬁbroadenoma,  hamartoma  and  cysts)
uring  pregnancy.
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reast lumps during pregnancy
linical examination
hen  a  patient  consults  for  a  palpable  lump  that  she  has
etected,  she  should  be  questioned  and  thoroughly  exam-
ned  in  order  to  conﬁrm  the  presence  of  a  mass,  describe
t  and  prescribe  the  appropriate  complementary  investiga-
ions.
Questioning  should  be  aimed  at  determining  the  date  of
ppearance  of  the  lump,  as  well  as  individual  patient  history
possible  known  ﬁbroadenoma)  and  familial  history.
Clinical  examination  is  based  on  careful  breast  inspection
nd  palpation  and  comparison  with  the  contralateral  side  to:
conﬁrm  the  presence  of  the  mass;
identify  its  location  and  size;
describe  its  consistency  and  mobility;
detect  related  signs:  skin  retraction,  nipple  changes,  dis-
charge,  lymph  nodes,  signs  of  inﬂammation,  pyrexia.
Finding  a  breast  lump  in  a  young  pregnant  woman  whose
ind  is  already  set  on  the  upcoming  birth  is  a  particularly
psetting  and  stressful  situation.  Everybody,  including  the
atient,  her  family  but  also  the  clinician,  would  prefer  to  say
‘it’s  nothing’’,  ‘‘we  shall  see  once  the  baby’s  been  born’’.
However,  since  the  patient  brought  herself  to  consult,
omething  is  already  wrong  —  the  rot  has  set  in  —  and  the
roblem  must  be  resolved  now,  during  pregnancy.
Why?  Because  in  the  great  majority  of  cases  (80%)  the
ump  is  benign  [3]  and  the  patient  can  be  reassured  and
ontinue  her  pregnancy  relieved.  And  when  it  is  cancer,  the
elay  in  diagnosis  (still  very  frequent)  due  to  postponing
nvestigations  until  after  delivery,  may  have  serious  conse-
uences.
Indeed,  the  types  of  cancer  that  typically  occur  during
regnancy  are  very  often  aggressive  and  require  fast,  multi-
isciplinary  management.  Breast  specialists  consider  it  to  be
ne  of  the  rare  ‘‘breast  emergencies’’.  Clinicians  should  also
e  aware  that  efﬁcient  treatment  of  the  mother  is  possible,
nd  can  generally  be  implemented  during  pregnancy.
maging ﬁndings during pregnancy [3—10]
he  consistency  of  clinical  and  imaging  ﬁndings  regarding
ump  location,  size  and  shape  should  always  be  veriﬁed.
ltrasound
ltrasound  is  used  as  the  ﬁrst-line  imaging  technique.  It
nables  accurate  diagnosis  of  simple  cystic  lesions  and  some-
imes  helps  to  conﬁrm  the  clinician’s  feeling  that  there  is
ctually  no  lump  but  just  normal  ﬁbroglandular  tissue.  It
llows  accurate  investigation  of  solid  lesions.
Benign  lesions,  particularly  ﬁbroadenomas  and  hamar-
omas,  may  increase  in  size  during  pregnancy,  become
eterogeneous  and  undergo  infarction.  They  may  therefore
ook  suspicious  by  imaging  techniques  so  if  in  doubt  samples
hould  be  obtained.ammography
hen  4-view  mammography  is  performed,  the  mother
eceives  a  dose  of  radiation  of  about  3  mGy  and  the  dose
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aBreast  lumps  in  pregnant  women  
received  by  the  uterus  is  lower  than  0.03  Gy  [6].  The  fetus
is  therefore  exposed  to  a  negligible  amount  of  radiation
[3—5]  of  about  0.001  to  0.01  mGy,  that  is  0.03  to  0.3  mSv
(depends  on  fetal  weight  and  term,  etc.).  This  level  of  expo-
sure  should  be  compared  with  the  natural  weekly  radiation
that  the  fetus  receives  that  is  estimated  at  0.02  mGy  [8].
Doses  of  up  to  1  mGy  are  considered  to  be  acceptable  for
the  fetus  [7].  The  threshold  value  above  which  there  exists  a
risk  for  the  fetus  is  50  mGy.  Mammography  may  be  performed
with  a  lead  screen  or  apron  that  approximately  halves  the
dose  to  the  fetus  and  reassures  the  patient.  Nevertheless,
even  if  the  patient  is  unaware  that  she  is  pregnant  and  mam-
mography  is  performed  without  a  lead  screen  there  is  no  risk
for  the  fetus  [6].
Mammography  should  be  prescribed  on  even  the  slightest
doubt  after  clinical  and/or  ultrasound  examination,  because
it  can  be  particularly  useful  for  diagnosis  in  cases  of  breast
cancer  [8].  Moreover,  if  a  lesion  contains  fatty  density,  its
benignity  can  be  afﬁrmed  and  biopsy  avoided.
MRI
On  the  basis  of  current  knowledge,  the  injection  of
gadolinum,  as  is  required  for  breast  MRI,  is  contraindicated
during  pregnancy.
Breast samples [9,11]
It  is  essential  that  pathologists  be  aware  that  the  patient  is
pregnant  before  assessing  breast  samples.
Cytological assessment
Pregnancy  can  lead  to  false  negative,  as  well  as  false  positive
results.  False  positives  are  due  to  atypical  nuclear  ﬁndings
(lactational  hyperplasia,  nucleus  enlargement,  hyperchro-
mia)  and  the  signiﬁcant  cell  mitosis  that  is  observed.  If
atypical  ﬁndings  are  observed,  they  should  not  be  imputed
to  pregnancy  without  additional  proof;  taking  a  biopsy  is
mandatory  in  these  cases.
Fine  needle  aspiration  may  be  useful  for  investigating
painful  cysts  with  thick  ﬂuid  contents  or  if  an  abscess  is
suspected.
Biopsy
Taking  biopsies  is  the  most  reliable  method  for  diagnos-
ing  solid  masses.  Biopsies  are  generally  performed  using
ultrasound  guidance  but  are  sometimes  also  carried  out
using  stereotactic  guidance  (microcalciﬁcations).  In  the  lat-
ter  case,  there  is  a  slightly  higher  rate  of  complications  (milk
ﬁstula,  infection  or  bleeding),  and  post-biopsy  compression
should  be  applied  for  a  longer  time.
Main etiologiesIn  the  great  majority  of  cases,  breast  lumps  in  pregnant
women  are  of  benign  nature.
A  variety  of  speciﬁc  etiologies  are  observed  in  pregnant
women:
c
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lactating  adenoma;
galactocele;
infarction  (of  a preexisting  lesion  or  of  healthy
parenchyma);
macromastia  (very  rare).
Other  etiologies  are  common  in  women  of  this  age  group
average  age:  20  to  40  years):
ﬁbroadenoma;
cystic  disease;
more  rarely  hamartoma,  mastitis,  abscess,  etc.  (or  any
other  breast  disease);
breast  cancer,  which  is  rare  but  with  serious  consequence
and  often  diagnosed  at  a  late  stage.  Cancer  must  be
excluded  in  pregnant  women  as  it  is  one  of  the  rare
‘‘breast  emergencies‘‘.  As  indicated  by  R.  Vashi  [5],  the
radiologist’s  most  urgent  role  is  to  avoid  a delay  in  diag-
nosis.
Clinicians  should  be  aware  that  after  childbirth  and
reast-feeding,  many  benign  abnormalities  regress  sponta-
eously.
actating adenoma [3,12]
actating  adenoma  is  benign  tumor  that  usually  causes  a
ingle  mass,  however  bilateral  and  multiple  adenomas  can
e  found.  It  occurs  during  the  third  trimester  of  pregnancy
rarely  the  ﬁrst  or  second  trimester),  as  well  as  during
reast-feeding,  and  regresses  once  the  patient  stops  breast-
eeding.  It  is  characterized  by  a  painless,  mobile  mass  that
ay  become  hard  and  painful  when  associated  with  infarc-
ion.
Macroscopically,  the  masses  are  yellow,  lobulated  and
ell-delimited  with  no  capsule.  Microscopic  investigation  of
actating  adenoma  reveals:
proliferation  of  secretory  lobules  separated  by  thin  layers
of  connective  tissue;
alveolar  lumen  ﬁlled  with  proteins,  lipids  and  colostrum;
a  double  layer  of  epithelial  and  myoepithelial  cells.
Immunohistochemistry  shows  strong  binding  of  the  S100
rotein.
Ultrasound  examination  shows  a  solid  mass  of  benign
ppearance  categorized  as  BI-RADS  3  (homogeneous  well-
elimited  hypoechoic  mass,  the  main  axis  of  which  is  parallel
o  the  skin),  which  mimics  ﬁbroadenoma.  It can  sometimes
e  difﬁcult  to  differentiate  the  lesion  from  adjacent  ﬁbrog-
andular  tissue.
Rarely,  atypical  ﬁndings  are  observed,  in  particular:
zones  of  anechoic  ﬂuid;
poorly-deﬁned  borders  (no  capsule);
heterogeneous  contents  (secretory  cells).
When  visible  on  mammograms,  lactating  adenoma  shows
p  as  a  well-deﬁned  mass.  It  is  sometimes  of  fat  density  or
ther  times  shows  a  ﬂuid-fat  level  (because  the  secretory
obules  contain  colostrum)  and  can  therefore  be  diagnosed
s  benign.
If  the  clinical  appearance  and  ultrasound  ﬁndings  are
haracteristic  (solid  BI-RADS  3  mass),  then  the  patient  may
e  reassured  although  followed-up  closely  (clinical  exam-
nation  and  ultrasound).  As  previously  discussed,  biopsy  is
ometimes  necessary  when  ultrasound  ﬁndings  are  atypical
1 A.  Langer  et  al.
(
r
G
A
o
t
c
n
b
g
a
p
•
•
•
•
w
t
a
s
B
D
t
m
•
•
•
d
l
s
o
l
Figure 2. Thirty-four year-old patient, 2nd trimester of 2nd preg-
nancy, no family history with a palpable lump. History of lactating
adenoma diagnosed and biopsied during ﬁrst pregnancy in 2012. It
then measured 37 × 35 mm and has grown to now measure 60 × 40
mm. Ultrasound ﬁndings: mass with large axis in horizontal plane,
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Fig.  1a—c)  (and  the  lesion  does  not  contain  fat  on  mammog-
aphy)  and/or  if  the  lesion  changes  signiﬁcantly  (Fig.  2).
alactocele [3,9]
 galactocele  is  a  retention  cyst  containing  milk,  which
ccurs  when  a  milk  duct  becomes  obstructed  (generally  due
o  inﬂammation).  Although  most  frequently  observed  after
hildbirth,  it  can  occur  during  the  third  trimester  of  preg-
ancy  or  during  breast-feeding.  Clinically,  it  is  reﬂected
y  a  single  mass  or  multiple  masses.  Using  ultrasound,
alactoceles  are  visualized  as  round  or  oval  structures,  the
ppearance  of  which  depends  on  the  proportions  of  ﬂuid,
rotein  and  fat  that  they  contain.  Galactoceles  can  be:
anechoic;
contain  a  ﬂuid-fat  level;
hypoechoic  or  with  ﬁne  echos;
of  complex  geometry  with  a  thick  wall  (inﬂammation).
When  visible  on  mammograms,  galactocele  shows  up  as  a
ell-deﬁned  mass  of  fat  or  ﬂuid  density  (Fig.  3a—c),  some-
imes  with  a  fat-ﬂuid  level,  and  can  therefore  be  diagnosed
s  benign.
Clinical  examination  and  ultrasound  imaging  are  usually
ufﬁcient,  but  if  in  doubt,  cytology  ascertains  the  diagnosis.
reast infarction
uring  pregnancy,  necrosis  and  bleeding  may  occur  in  hyper-
rophic  breast  tissue  (Fig.  4)  or  inside  another  preexisting
ass  (known  or  unknown).  Infarction  generally  occurs  in:
ﬁbroadenoma;
lactating  adenoma;
hamartoma.
The  clinical  signs  may  seem  suspicious  with  a poorly-
eﬁned,  painful  mass  that  can  adhere  to  the  skin  and  cause
ymph  node  enlargement  (inﬂammatory  response  to  necro-
is).
Using  imaging  techniques,  the  mass  appears  solid  and
ften  heterogeneous,  and  can  be  associated  with  axillary
ymphadenopathy.
M
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igure 1. Twenty-six year-old patient, 8th month of pregnancy, no f
uadrants: a: ultrasound showing an oval-shaped mass, the larger axis o
nhancement, BI-RADS 4a; b and c: bilateral mammograms (MLO view)
esion classiﬁed ACR4a. Ultrasound-guided microbiopsy evidenced lactaticrolobulated borders, BI-RADS 4. Ultrasound-guided microbiopsy
videnced lactating adenoma.
Biopsy  is  generally  required  due  to  the  presence  of  a  het-
rogeneous  solid  mass  (therefore  categorized  as  BI-RADS  4
r  5).  Fine  needle  aspiration  is  not  recommended  as  it  is  not
 reliable  method  owing  to  ischemic  necrosis.acromastia
acromastia  is  a  very  rare  condition  (1/100,000  pregnan-
ies).  It  is  generally  bilateral,  of  unknown  etiology  and
amily history, with a palpable lump in the union of left internal
f which is horizontal, discreetly heterogeneous, without posterior
 showing dense breasts with a round, partially delimited, 40-mm
ing adenoma.
Breast  lumps  in  pregnant  women  1081
Figure 3. Forty-ﬁve year-old patient, last trimester of pregnancy, no family history, with a small lump in the union of right upper
quadrants: a: ultrasound showing a very hypoechoic round structure, without posterior enhancement, with well-deﬁned borders and a
discreetly irregular wall BI-RADS 4b; b and c: mammography (CC and MLO views) showing a translucency (consistent with the location and
size of the lesion), due to fatty content, and demonstrating its benign n
Figure 4. Twenty-eight year-old patient, no family history, with
a palpable lump during the ﬁrst trimester of pregnancy. Ultrasound
ﬁndings: well-delimited hypoechoic mass with a small anechoic cen-
tral zone and clear posterior enhancement. The shape is round and
there are bilateral cysts. The lesion is classiﬁed as BI-RADS 3, with
a decision of monitoring. It remains stable during pregnancy. The
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RADS  3).  In  such  cases,  clinical  and  ultrasound  follow-uplesion is biopsied due to its non-disappearance after childbirth:
breast parenchyma with milk-secreting lobules and ischemic necro-
sis.
causes  major  hypertrophy  of  the  breasts,  each  breast
weighing  up  to  7  kg  or  sometimes  even  more.  Besides  the
discomfort  caused  by  the  condition,  it  is  associated  with
serious  complications  such  as  ulcerated  skin  lesions,  breast
infarction,  bleeding  from  the  dilated  breast  vessels.
Diagnosis  is  made  by  clinical  examination;  biopsy  not
advised  because  of  the  risk  of  secondary  infection  and  bleed-
ing.  Histologically,  the  condition  is  due  to  an  increase  of  the
volume  of  breast  gland  and  connective  tissue  but  not  of  the
adipose  tissue.
Macromastia  patients  receive  drug  therapy  (bromocrip-
tine)  but  sometimes  breast  reduction  surgery  is  required.Fibroadenoma
Fibroadenoma  is  the  most  frequently  observed  tumor  during
pregnancy.  It  can:ature: galactocele.
appear  de  novo;
preexist  and  increase  in  size  due  to  the  high  levels  of
estrogens;
become  infarcted  (mainly  large  ﬁbradenomas).
Clinical  examination  reveals  a  hard,  mobile  lump  that
ecomes  painful  and  non-mobile  if  infarcted.
It  has  a  typical  BI-RADS  3  appearance  using  ultra-
ound  (oval  shape,  main  axis  parallel  to  skin,  hypoechoic
nd  homogeneous,  well-delimited  with  possible  posterior
nhancement).  During  pregnancy  more  atypical  ﬁndings
an  be  observed  due  to  ischemic  changes,  bleeding  and
ncreased  size.  The  ﬁbroadenoma  can  therefore  appear  het-
rogeneous  with  poorly-deﬁned  or  unclear  borders  and  a
uid  component  [10].
Further  investigation:
if  discovered  during  pregnancy:
◦ ﬁbroadenomas  of  typical  appearance  (BI-RADS  3)  can
either  be  simply  monitored  closely  (clinical  examina-
tion  and  ultrasound  every  1—2  months)  or  biopsied  to
avoid  the  stress  related  to  regular  monitoring.  The
course  of  action  depends  on  the  setting  (risk  factors,
anxiety)  as  well  as  local  practice  and  lesion  size.  Thus
a  10-mm  BI-RADS  3  mass  will  more  often  be  monitored
whereas  for  a  30-mm  lesion  biopsy  might  be  the  pre-
ferred  option,
◦ ﬁbroadenomas  of  atypical  appearance  (≥  BI-RADS  4)
require  biopsy;
if  ﬁbroadenoma  was  diagnosed  prior  to  pregnancy
(retrieve  imaging,  puncture  and  biopsy  results):
◦ if  stable,  monitoring  is  not  required,
◦ a 20%  increase  in  size  compared  with  previous  imaging
is  acceptable  [3]  if  the  appearance  is  still  benign  (BI-should  be  scheduled  and  the  patient  reassured,
◦ biopsies  should  be  collected  if  in  doubt  (substantial
increase  in  size,  morphological  change,  ambiguous)
(Fig.  5a—b);
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Figure 5. Twenty-six year-old patient, 4th month of pregnancy
with a mobile painless lump of the left superolateral quadrant. The
patient indicates that she has had this mass for 6 years (no imaging
ﬁndings), but that its size has recently increased. No family history:
a: ultrasound showing a well-delimited round mass with posterior
enhancement, an oblique larger axis and heterogeneous structure.
Categorized BI-RADS 4a; b: Mammography, MLO view, dense breast
containing a round well-delimited mass with a macrocalciﬁcation,
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Figure 7. Thirty-four year-old patient, 2nd month of pregnancy
with a painful 30-mm lump of the left upper quadrant and a familial
history of breast cancer (mother at age 59). Ultrasound examina-
tion categorized as BI-RADS 3 (complicated cyst), conﬁrmed by ﬁne
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fI-RADS 3. Biopsy evidenced ﬁbroadenoma.
if there  are  multiple  ﬁbroadenomas:
◦ usually  monitoring  (clinical  and  ultrasound)  is  rec-
ommended  in  presence  of  multiple  nodules  classiﬁed
BI-RADS  3,
◦ if  in  doubt,  the  most  suspicious  nodule  can  be  biopsied
(Fig.  6),
◦ if  the  diagnosis  of  ﬁbroadenoma  is  conﬁrmed,  the  other
nodules  should  be  monitored.
igure 6. Thirty-year-old patient with familial risk factors fol-
owed for probable multiple ﬁbroadenoma of the right breast since
010. Ultrasound examination at 4th month of pregnancy: enlarge-
ent of one of the nodules (9 mm in 2011, 22 mm at present),
till categorized as BI-RADS 3. In addition, two other nodules
ere observed (not shown): an unchanged 8-mm BI-RADS 2 nod-
le and 9-mm BI-RADS 3 nodule that was not described previously.
t was decided to biopsy the enlarged nodule. Biopsy evidenced
broadenoma with peripheral foci of lactating metaplasia. The 9-
m BI-RADS 3 nodule was monitored using ultrasound at 6 and 8
onths then after childbirth. It remained stable.
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ibrocystic disease
here  are  no  real  differences  with  cystic  disease  in  non-
regnant  women.  Cysts  can  be  simple  or  complicated,  single
r  multiple.  The  term  ‘‘complicated’’  should  only  be  used
or  cysts  of  thick  ﬂuid  contents  and  no  wall.
Puncture  can  be  performed  to  diagnose  complicated  cysts
Fig.  7) as  well  as  to  drain  pressurized  and/or  painful  cysts.
amartoma
n  most  cases,  ultrasound  ﬁndings  are  typical  (soft,  painless
ass:  ‘‘breast-in-breast’’  appearance)  and  hamartoma  can
e  diagnosed.  However  diagnosis  can  be  more  challenging
f  its  size  increases  and/or  its  appearance  changes  (associ-
ted  infarction).  In  such  cases,  hamartomas  are  visualized
s  atypical  solid  masses.  Mammographical  assessment  may
e  helpful  by  revealing  fatty  density  and  therefore  it  can
e  diagnosed  as  benign.  If  this  is  not  the  case,  then  biopsy
hould  be  performed.
astitis, abscess
onditions  of  infectious  origin  are  rare  during  pregnancy;
hey  are  more  frequent  during  breast-feeding.  Diagnosis  is
ased  on  clinical  signs:
inﬂammation  (redness,  heat,  pain);
painful  lump  (abscess);
axillary  lymph  node  enlargement;
fever,  hyperleukocytosis.
As  for  all  cases  of  breast  inﬂammation,  biopsies  should
e  taken  if  the  patient  does  not  respond  quickly  to  drug
reatment  (antibiotics,  10  days).
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Pregnancy-associated breast cancer (PABC)
[13—23]
PABC  is  deﬁned  as  breast  cancer  that  occurs  during  preg-
nancy  or  within  the  year  following  childbirth.  It  is  a  rare
disease  that  accounts  for  only  6—10%  of  all  breast  cancers  in
women  aged  under  40  years.  Only  a  small  proportion  of  cases
occur  during  pregnancy  (approx.  20%),  most  are  detected
post-parturition.  The  average  age  of  onset  is  34  years.  In
about  a  third  of  cases,  PABC  is  diagnosed  in  women  with  a
moderate  to  high  risk  of  breast  cancer.  Patient  questioning
on  familial  history  is  therefore  essential  and  women  with  a
signiﬁcant  risk  should  be  examined  carefully.  For  this  rea-
son,  Chopier  and  Rouzier  [19]  recommended  that  genetic
investigation  be  carried  out  systematically  for  patients  with
PABC.  Nonetheless,  in  the  great  majority  of  cases,  breast
cancer  occurs  in  young  women  with  no  noteworthy  history,
so  the  possibility  of  cancer  should  not  be  excluded  in  a  25-
year-old  woman  just  because  she  has  no  family  history  of  the
disease.
Generally  the  patient  consults  for  a  large  (or  even  very
large)  palpable  lump  that  she  discovered  herself.  Invasive
carcinoma  (that  can  be  associated  with  carcinoma  in  situ)  is
a
i
t
Figure 8. Thirty-eight year-old patient, 6th month of twin pregnancy w
quadrant staged T2 N0. Familial history of breast cancer (cousin at age
that the lead apron is visible) revealed dense breasts (type 4) with as
quadrant (BI-RADS 4). Ultrasound (e) showed a mass with microlobulate
RADS 4). Biopsy evidenced grade 3 RH+ Her2— invasive ductal carcinom
(ﬁrst 2 sessions during pregnancy), then after childbirth at 8 months by
radiotherapy and tamoxifen. Still in remission 6 years later.1083
sually  diagnosed  with  poor  prognosis  factors  [16]:  lymph
ode  involvement,  high-grade  tumors,  hormone-receptor
egative  and  HER2  positive.
Lesions  are  generally  categorized  as  BI-RADS  4  or  5  by
ltrasound  examination.  Even  so,  the  appearance  of  PABC
s  not  always  typical  of  malignancy.  Ayyappan  et  al.  [15]
eported  the  high  frequency  of  lesions  having  a  horizon-
al  main  axis  (60%)  and  posterior  enhancement  (60%).  This
s  probably  due  to  the  high  proportion  of  rapidly  devel-
ping  grade  3  inﬁltrating  ductal  carcinomas  that  progress
oo  quickly  to  induce  stromal  reaction  (Fig.  8a—e).  Analysis
f  the  borders  should  be  particularly  meticulous,  and  any
esion  with  microlobulated  and/or  irregular  borders  should
e  categorized  as  at  least  BI-RADS  4.  In  high-risk  patients,
specially  BRCA1  mutation  carriers,  breast  cancers  are  often
f  pseudo-benign  appearance,  and  biopsy  should  be  per-
ormed  if  even  the  slightest  doubt  exists  (Fig.  9a—b).  On  rare
ccasions,  ultrasound  does  not  perform  well  [16], especially
f  the  lesion  does  not  have  a  typical  malignant  appear-
nce  or  if  the  condition  is  exclusively  or  predominately
ntraductal.
It is  interesting  to  note  that  mammography  contributes
o  diagnosis  in  all  studies  (75—80%  of  cases  with  lesions
ith a palpable, clinically suspicious lump of the right superolateral
 40). Mammography (CC views [a, b] and MLO views [c, d]; note
ymmetrical density of convex margins of the right superolateral
d borders and a hyperechoic halo and posterior enhancement (BI-
a (IDC). The patient was treated with neoadjuvant chemotherapy
 caesarian section, tumor resection, axial lymph node dissection,
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Figure 9. Thirty-six year-old patient with BRCA1 mutation, 6th month of pregnancy. Recent appearance of a solid mass within the left
superolateral quadrant with a hard 1-cm axillary lymph node. a, b: mammograms (MLO view, note that the lead apron is visible) show dense
breasts with a spiculated structure in the upper left breast. Post-biopsy (benign) markers in the right breast; c: ultrasound revealing a
homogeneous, hypoechoic oval-shaped mass with microlobulated borders, BI-RADS 4b; d: ultrasound of the left axillary region: suspicious
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round lymph node showing cortical thickening and no hilum. Ultras
videnced grade 3 N+ IDC. The patient was treated by tumor resec
hemotherapy, radiotherapy, and hormone therapy.
lassiﬁed  BI-RADS  4  or  5)  despite  high  breast  density.  Indeed,
ither  the  mass  is  visible  on  the  mammogram  (often  with
nclear  and  sometimes  spiculated  borders)  or  architec-
ural  distortion  and/or  irregular  microcalciﬁcations  can  be
bserved.  In  the  series  we  reported  previously  [16],  55%
t
i
b
igure 10. Thirty-seven year-old patient, begining (6 weeks ameno
ight superolateral quadrant staged T2 N1; a: mammography (CC view); 
umerous, irregular and polymorphic microcalciﬁcations (BI-RADS 5). Biop
ith the patient, therapeutic abortion was performed, then mastecto
adiotherapy and hormone therapy. Still in remission 7 years later.-guided microbiopsy and ﬁne needle aspiration of the lymph node
and axial lymph node dissection, then after childbirth by adjuvant
f  patients  had  suspicious  microcalciﬁcations  which  con-
ributed  to  diagnosis  (Fig.  10a—b).
For  this  reason,  if  clinical  and/or  ultrasound  ﬁndings  are
nconclusive  or  suspicious,  bilateral  mammography  should
e  performed.  In  our  study,  we  used  both  CC  and  MLO
rrhea) of 4th pregnancy with a clinically suspicious lump of the
b: mammography (enlarged image) showing a spiculated mass with
sy evidenced grade 3 IDC and high grade DCIS. Following discussion
my and axial lymph node dissection followed by chemotherapy,
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views  for  each  breast.  Out  of  the  22  cases  of  breast  cancer
detected  during  pregnancy,  mammography  caught  up  for  the
ultrasound  false-negatives  and,  vice-versa,  ultrasound  found
the  cancers  missed  by  mammography  [16].
Patients  may  be  treated  surgically  at  any  time  during
pregnancy  and  chemotherapy  may  be  initiated  from  the  2nd
trimester  on.  The  main  risk  for  the  fetus  is  prematurity.  Even
if  little  is  known  about  the  long-term  effects  on  the  child,
none  of  the  studies  carried  out  reported  signiﬁcant  excess
mortality  or  morbidity.  Radiotherapy  is  generally  contraindi-
cated  during  pregnancy,  as  is  hormone  therapy.
Numerous  different  oncological,  obstetrical,  psycholog-
ical  and  personal  parameters  (choice,  mother’s  age,  other
children,  risk  factors)  need  to  be  taken  into  account.  Ther-
apeutic  abortion  does  not  improve  the  patient’s  prognosis,
and  should  be  considered  on  a  case-by-case  basis.  It  may  be
recommended  at  the  very  beginning  of  pregnancy  for  severe
forms  of  breast  cancer  if  prognosis  would  be  worsened  by
delaying  chemotherapy  until  the  4th  month.
In practice
Following  patient  questioning  and  careful  clinical  examina-
tion,  bilateral  ultrasound  is  used  as  the  ﬁrst-line  imaging
technique.  The  next  steps  depend  on  ultrasound  ﬁndings.
If ultrasound reveals a typical BI-RADS 2 cyst
(cyst, galactocele)
The  patient  can  be  reassured  and  further  investigation  is  not
needed.
If ultrasound reveals a lesion classiﬁed
BI-RADS 5
As  for  non-pregnant  patients,  complete  bilateral  mammog-
raphy  should  be  performed  and  ultrasound-guided  biopsy
samples  collected.
Normal ultrasound ﬁndings
If  ultrasound  ﬁndings  are  normal,  consistent  with  the  clin-
ical  examination  and  no  real  mass  is  detected,  then  the
patient  should  be  reassured.  The  obstetrician  will  continue
to  examine  the  breasts  regularly  during  normal  pregnancy
visits.
On  the  other  hand,  if  clinical  ﬁndings  are  ambiguous  or
suspicious  (mass,  related  signs),  then  bilateral  mammogra-
phy  should  be  performed,  and  if  still  in  doubt  biopsies  taken.
Robbins  [8]  reported  that  the  negative  predictive  value  (for
PABC)  of  the  combination  of  mammography  and  ultrasound
was  100%.  In  the  series  of  patients  we  studied  [16],  mam-
mographic  and  ultrasound  ﬁndings  were  never  both  negative
for  patients  with  breast  cancer.Complicated cyst classiﬁed BI-RADS 3
Stringent  criteria  need  to  be  applied:
l
m
d
m1085
round-  or  oval-shaped  lesion;
uniformly  hypoechoic  or  with  ﬁne  echos;
well-deﬁned  borders;
posterior  enhancement;
no  wall.
Depending  on  local  practice  and  the  clinical  setting,  the
esion  is  either  punctured  in  order  to  diagnose  a  thick-ﬂuid
yst,  galactocele,  or  even  an  abscess,  or  monitored  by  regu-
ar  clinical  and  ultrasound  examination  (every  1—2  months).
typical  puncture  ﬁndings  should  not  be  attributed  to  preg-
ancy,  but  should  lead  to  biopsy  to  clarify  the  diagnosis.
One  must  be  careful  with  partly  ﬂuid  (complex)  masses,
hich  must  be  categorized  as  BI-RADS  4  and  not  BI-RADS
.  They  can  reﬂect  changes  in  a  benign  lesion  (ﬁbroade-
oma,  hamartoma,  lactating  adenoma,  infarction)  but  also
ecrotic  cancer.
olid mass of benign appearance classiﬁed
I-RADS 3
epending  on  local  practice,  clinical  setting  (patient  at  risk)
nd  lesion  size,  there  are  three  possibilities:
regular  clinical  and  ultrasound  monitoring  (every  1—2
months,  to  rapidly  detect  a  progressing  lesion);
mammography  (MLO  view  ±  CC  view)  to  ensure  there  are
no  suspicious  structures  (particularly  microcalciﬁcations)
and  increase  diagnostic  conﬁdence,  or  even  reclassify  the
lesion  as  BI-RADS  2  (fatty  density);
immediate  biopsy.
Masses  categorized  as  BI-RADS  3  generally  reﬂect
broadenoma,  lactating  adenoma,  hamartoma  or  galac-
ocele.  Nevertheless,  caution  should  be  observed  when
iagnosing  breast  masses  in  BRCA1  mutation  carriers.
olid mass of indeterminate or suspicious
ppearance classiﬁed BI-RADS 4
ammography  (MLO  view  ±  CC  view)  should  be  performed.
f  the  mass  shows  partially  fatty  density  and/or  a  ﬂuid-
at  level,  it  can  be  reclassiﬁed  BI-RADS  2  and  the
atient  reassured.  In  all  other  cases,  biopsy  should  be
erformed.
When  biopsy  results  are  benign  and  consistent  then  the
atient  should  be  reassured.  A  control  ultrasound  examina-
ion  can  be  scheduled  after  childbirth,  but  is  not  urgent.
However  if  the  biopsy  reveals  the  presence  of  malig-
ant  tissue,  exhaustive  bilateral  mammography  must  be
erformed  without  fail  if  not  already  done  (at  least  two
iews  per  breast)  so  as  not  to  miss  any  homolateral  or  con-
ralateral  microcalciﬁcations.
onclusion
reast  masses  discovered  during  pregnancy  should  be  inves-
igated  immediately  either  to  reassure  the  patient  (most
esions  are  benign),  or  if  necessary,  rapidly  implement  treat-
ent  when  breast  cancer  is  diagnosed  since  any  delay  in
iagnosis  and  therapy  can  jeopardize  successful  manage-
ent.
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Take-home  messages
Palpable  breast  lumps  in  pregnant  women
• It  is  a  frequent  and  stressful  situation.  Investigation
should  be  immediate  and  not  delayed  until  after
childbirth.
• Most  lesions  are  benign  (80%).  They  are  either:
◦ common  in  women  of  this  age  group:  notably
ﬁbroadenoma,  cyst,  hamartoma,
◦ or  related  to  pregnancy:  lactating  adenoma,
galactocele,  infarction  of  a  benign  lesion.
• Breast  cancer  is  a  rare  but  serious  disease;  it  needs
to  be  excluded  without  delay.
Imaging
• Ultrasound  is  the  ﬁrst-line  imaging  technique.
• Mammography  is  indicated:
◦ if there  is  the  slightest  doubt  after  clinical  and/or
ultrasound  examination,
◦ despite  high  breast  density,  mammography  very
often  contributes  to  the  diagnosis  of  cancer,
and  its  results  are  complementary  to  ultrasound
(microcalciﬁcations),
◦ if  the  lesion  is  found  to  be  of  fatty  density  it
can  be  reclassiﬁed  as  BI-RADS  2  and  biopsy  is  not
required  (some  lactating  adenomas,  galactoceles
and  hamartomas);
◦ it incurs  no  risk  for  the  embryo  or  the  fetus.
• Due  to  ischemic  changes  and  bleeding  and/or  an
increase  in  size  during  pregnancy,  some  benign
lesions  may  appear  as  ambiguous  and  require  biopsy.
Collecting  samples
• Fine  needle  aspiration  should  only  be  used  for  cystic
lesions,  and  clinicians  should  be  aware  of  the  risk  of
false-negative  and  false-positive  results.
• Depending  on  local  practice  and  the  clinical  setting,
solid  lesions  classiﬁed  BI-RADS  3  should  be  monitored
regularly  by  ultrasound  (every  1—2  months),  or
biopsied.  Biopsies  must  be  collected  for  lesions
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Lesion  in  the  right  lower  quadrant:  pseudotumoral  scle-
F
l
qclassiﬁed  BI-RADS  4  or  BI-RADS  5.
linical caseorty-one  year-old  patient,  7th  month  of  pregnancy,  consul-
ing  for  a  palpable  lump  in  the  right  superolateral  quadrant
hat  appeared  2  months  ago.  Palpation  was  difﬁcult  during
igure 11. Forty-one year-old patient, 7th month of pregnancy, 25-mm
ump in the right superolateral quadrant (axillary lymph node not show
uadrant.A.  Langer  et  al.
linical  examination.  The  mass  measured  25  mm  and  homo-
ateral  axillary  lymph  node  enlargement  was  observed.
ltrasound  examination  (Fig.  11)  revealed:
a structure  consistent  with  the  palpable  mass  in  the  right
superolateral  quadrant  (axillary  lymph  node  not  shown);
a  mass  in  the  right  lower  quadrant;
a  mass  in  the  left  upper  quadrant.
uestions
.  Should  mammography  be  performed?
.  How  would  you  classify  these  lesions?
.  What  is  the  appropriate  management  of  this  patient:
monitoring,  biopsy,  multiple  biopsies?
nswers
.  Yes,  because  the  clinical  ﬁndings  are  suspicious  (mass
associated  with  a  palpable  lymph  node)  and  ultrasound
ﬁndings  >  BI-RADS  3.  Bilateral  mammographic  ﬁndings
were  normal  (not  shown).
.  The  main  axis  of  the  lesion  in  the  right  superolateral
quadrant  is  horizontal  but  it  is  heterogeneous  and  its
borders  are  microlobulated:  BI-RADS  4.  The  lesion  in  the
right  lower  quadrant  is  oval,  well-delimited  and  homoge-
neous:  BI-RADS  3.  The  lesion  in  the  left  upper  quadrant
is  bilobed  but  its  main  axis  is  vertical  and  its  borders  are
discreetly  irregular:  BI-RADS  4.
.  Both  lesions  classiﬁed  BI-RADS  4  should  be  biopsied.  The
lesion  classiﬁed  BI-RADS  3  can  simply  be  monitored  if  the
two  others  are  found  to  be  benign.  This  patient  was  from
Cameroon  and  needed  a  deﬁnitive  result  before  retur-
ning  home  (monitoring  not  possible):  all  three  lesions
were  therefore  biopsied  and  the  right  axillary  lymph  node
punctured.
.  The  following  results  were  obtained:  Lesion  in  the
right  superolateral  quadrant:  secretory  metaplasia  of
the  breast  parenchyma  with  numerous  foci  of  pseu-
doangiomatous  stromal  hyperplasia  (PASH).  Fine  needle
aspiration  biopsy  of  axillary  lymph  node:  benign  reac-
tion.  Lesion  in  the  left  upper  quadrant:  ﬁbroadenoma.rosing  adenosis.  All  the  lesions  were  in  fact  benign  and
the  patient  was  free  to  leave  without  requiring  follow-
up.
 mass with homolateral axillary palpable lymph node: a: palpable
n); b: mass in the lower right quadrant; c: mass in the upper left
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